skip to content

research · 500124 · healthcare

drreddy.

the case for, the case against.

neutralmedium convictionwritten 16 nov 2026, 17:21 ist · valid until 23 nov 2026

neutral: the evidence is mixed or thin. that is a useful answer too. medium conviction: a reasonable case, resting on fewer or partly second-hand sources.

the evidence, in short
  • Dr. Reddy's consolidated revenues for Q2FY27 were ₹86,708 Mn, down 1.5% YoY and up 7.4% QoQ.

the main risk
  • North America revenue was ₹24,890 Mn in Q2FY27, against ₹32,408 Mn in Q2FY26.

in plain words

Dr. Reddy's consolidated revenues for Q2FY27 were ₹86,708 Mn, down 1.5% compared with the same period a year earlier and up 7.4% compared with the previous quarter. North America revenue was ₹24,890 Mn in Q2FY27, against ₹32,408 Mn in Q2FY26. Gross margin was 52.1% in Q2FY27, compared with 54.7% in Q2FY26.

what the evidence shows

  • Dr. Reddy's consolidated revenues for Q2FY27 were ₹86,708 Mn, down 1.5% YoY and up 7.4% QoQ.

  • Branded businesses, namely India, Emerging Markets and the acquired consumer health portfolio in Nicotine Replacement Therapy, accounted for 53% of Q2FY27 revenues.

what could go wrong

  • North America revenue was ₹24,890 Mn in Q2FY27, against ₹32,408 Mn in Q2FY26.

  • Gross margin was 52.1% in Q2FY27, compared with 54.7% in Q2FY26.

  • Q1FY27 results were impacted by a ₹2,397 Mn provision towards inventory and associated costs related to semaglutide's active pharmaceutical ingredient.

price and valuation facts

  • Closed 0.4% below its 52-week closing high.
  • Last close ₹1,380 sits 98% of the way from the 52-week closing low (₹1,135.65) to the high (₹1,386).
  • Its largest fall from a peak in the last year was 17.5% (maximum drawdown).
  • P/E of 118.56x (standalone) is 81% above the median of its BSE 500 industry peers (sector peers when the industry has fewer than four).
  • Annualised volatility over 3 months is 22.0%, lower than 92% of the BSE 500 scrips Dalal tracks.
  • Median daily BSE traded value: ₹7.48 crore over 60 days.

dalal's own computed data (from exchange prices and bse fundamentals), not from the documents above. as of 16 nov 2026.

what is coming up

  • Brazil's National Health Surveillance Agency (ANVISA) granted Dr. Reddy's marketing authorization for generic semaglutide injection.

what would change the view

the view rests on these. if they stop being true, so does the view.

  • The USFDA classified the inspection outcome at the FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh as 'Voluntary Action Indicated (VAI)'.

the numbers

computed by dalal when the note was written.

price

last close
₹1,380.00
1-day change
0.22%
52-week high (closing basis)
₹1,386.00
52-week low (closing basis)
₹1,135.65
52-week high (BSE, adjusted)
₹1,414.40
52-week low (BSE, adjusted)
₹1,080.05

as of 16 nov 2026

returns

1-week return
−0.36%
1-month return
12.03%
3-month return
15.77%
6-month return
3.65%
12-month return
10.85%
3-month return relative to SENSEX
9.60%
6-month return relative to SENSEX
−4.92%
12-month return relative to SENSEX
14.17%

as of 16 nov 2026

risk

annualised volatility (3 months)
22.03%
maximum drawdown (1 year)
−17.49%
distance from 52-week closing high
−0.43%
5-day vs 60-day BSE volume
0.65×

as of 16 nov 2026

valuation

P/E (standalone)
118.56×
P/E (consolidated)
41.74×
P/B
4.28×
EPS (standalone)
₹11.64
EPS (consolidated)
₹33.06
P/E relative to industry median
1.81×

as of 16 nov 2026

quality

return on equity
3.61%
operating margin
23.54%
net margin
12.49%

as of 16 nov 2026

size & liquidity

median daily BSE traded value (60 days)
₹7 cr
market capitalisation
₹1,15,262 cr

as of 16 nov 2026

latest results (standalone)

revenue, standalone (Sep-26)
₹5,573 cr
net profit, standalone (Sep-26)
₹696 cr
EPS, standalone (Sep-26)
₹8.35
operating margin, standalone (Sep-26)
23.54%
revenue, standalone (Jun-26)
₹5,137 cr
net profit, standalone (Jun-26)
₹405 cr
EPS, standalone (Jun-26)
₹4.86
operating margin, standalone (Jun-26)
17.28%
revenue change Jun-26 → Sep-26
8.49%
net profit change Jun-26 → Sep-26
71.93%

as of 14 nov 2026

dalal scores

daily score
59/100
monthly score
99/100
six-month score
54/100
long-term score
65/100

as of 16 nov 2026

not available: next results board meeting; days since last results filing.

· · . fundamentals from bse are standalone figures. scores are percentile ranks across the bse 500 (90 = better than 90% of them on that horizon’s recipe). 7 statements passed dalal’s source checks. 3 did not and are not shown.

pick history

every time it was listed, and how it went.

never on a list so far.

in the knowledge base

the latest filings and news.

research ideas and things to consider, not personalised investment advice. every statement links to the filing or article it came from; numbers are computed by dalal from exchange data with their dates. ideas can and do lose money: the track record shows every pick, losers included. decide based on your own situation.